The PAX6 gene is involved in ocular morphogenesis and is expressed in the developing central nervous system and numerous ocular tissues during development. PAX6 mutations have been detected in various ocular anomalies, including aniridia, Peters anomaly, corneal dystrophy, congenital cataracts, and foveal hypoplasia. However, it has not been identified in patients with optic-nerve malformations. Here, we identified novel mutations in eight pedigrees with optic-nerve malformations, including coloboma, morning glory disc anomaly, optic-nerve hypoplasia/aplasia, and persistent hyperplastic primary vitreous. A functional assay demonstrated that each mutation decreased the transcriptional activation potential of PAX6 through the paired DNA-binding domain. PAX6 and PAX2 are each thought to downregulate the expression of the other. Four of the detected mutations affected PAX6-mediated transcriptional repression of the PAX2 promoter in a reporter assay. Because PAX2 gene mutations were detected in papillorenal syndrome, alternation of PAX2 function by PAX6 mutations may affect phenotypic manifestations of optic-nerve malformations.
Previous ophthalmoscopy and medical imaging studies have established a variety of clinical entities in optic-nerve malformation (Brown and Tasman 1983) , since numerous tissues and developmental events contribute to the optic-nerve architecture. The optic nerve first arises as the optic stalk between the forebrain and optic vesicle at 3 wk human gestation. At 5-6 wk, mesenchymes and vessels invade through the embryonic fissure, a transiently appearing ventral cleft of the optic stalk and optic cup, into the vitreous cavity. Nerve fibers of retinal ganglion cells then begin to project into the CNS at 8-10 wk. In the middle stage, the optic nerve is coated with a collagen sheath and propped up by glial cells, and the nerve head is transiently covered with glial cells and hyaloid vessels. In this series of events, developmental failure of the embryonic fissure (resulting in coloboma), ret-inal ganglion cells (optic-nerve hypoplasia/aplasia), and hyaloid vessels (persistent hyperplastic primary vitreous) cause disease (Brown and Tasman 1983) . Most of these anomalies are sporadic, but autosomal dominant inheritance has been reported in families with coloboma of the optic nerve (CON [MIM 120430] ) and optic-nerve hypoplasia (ONH [MIM 165550]) . Mutations causing autosomal dominant syndrome have been identified in two transcription factor genes. The PAX2 gene, one of nine known paired box genes, is expressed in the developing optic stalk, the ventral half of the optic cup, and the kidney, and its mutations cause papillorenal syndrome (PRS [MIM 120330]) (Sanyanusin et al. 1995) . HESX1 gene mutations, expressed in the ventral half of the forebrain, Ratke's pouch, and pituitary gland, were identified in patients with septo-optic dysplasia (SOD [MIM 182230]) (Dattani et al. 1998) . However, there has not been genetic interpretation of various manifestations of optic-nerve malformations.
The Pax6/PAX6 gene, first isolated as a candidate gene for human aniridia and expressed in developing CNS and various ocular tissues (Walther and Gruss 1991; Nishina et al. 1999) , encodes a transcription factor that is involved in eye morphogenesis (Gehring 1996) . Genetic analysis has detected numerous PAX6 mutations, not only in patients with aniridia but also with other eye anomalies (summarized in the Human PAX6 Mutation Database). In situ hybridization and immunohistochemistry indicated PAX6 expression in the developing optic nerve (Walther and Gruss 1991; Nishina et al. 1999) , and the small eye (Sey H ) mouse mutant with a deletion of the Pax6 locus showed coloboma, a defect of the initial invagination in the optic stalk and cup (Glaser et al. 1990 ). However, there is no evidence of PAX6 mutations in patients with optic-nerve malformations.
We screened for PAX6 mutations in genomic DNA from 155 individuals with a variety of congenital opticnerve malformations by use of PCR-SSCP analysis. PCR primers used to amplify PAX6 exons were synthesized on the basis of the reported sequence (Glaser et al. 1992) ; the primer sequences can be found in appendix A (online only), and the conditions of PCR and SSCP analyses were described elsewhere . Nucleotide sequences were determined directly or after cloning into plasmid pUC18 by use of a Sequenase version 2 kit (Amersham) with PCR primers or universal primers in pUC18. Eight mutations were detected.
Patient 1, a 5-year-old girl, had bilateral morning glory disc anomaly. Mutation analysis identified 619CrT nucleotide substitution (according to GenBank accession number M93650), which is expected to result in P68S ( fig. 1a) . Patient 2, a 21-year-old male, had bilateral ONH and 1030CrT (Q205X) (fig. 1b) . Patient 3, a 1-yearold boy, had an iris anomaly, large coloboma of the optic nerve, retina, and choroids, a remnant of hyaloid vessel proliferation (persistent hyperplastic primary vitreous) bilaterally, and growth and mental retardation; mutation analysis identified 1190TrC (F258S) ( fig. 1c) . Patient 4, a 2-year-old boy, had bilateral ONH, growth and mental retardation, an enlarged ventricle by computed tomography (CT) study, multiple spike and wave bursts by electroencephalogram, and vesicoureteral reflux; mutation analysis identified 1292GrT (S292I) ( fig. 1d ). Patient 5, a 1-year-old girl, had Peters anomaly in the left eye and slight corneal opacity, deep excavation of the optic-nerve head in the right eye, and 1504TrC (S363P) ( fig. 1e ). Patient 6, a 2-mo-old girl, had microphthalmos in the right eye, iris dysplasia and optic-nerve aplasia with a remnant of the hyaloid vessels in the left eye, and 1550ArG (Q378R) ( fig. 1f ). Patient 7, a 19-year-old male, had bilateral ONH and 1558ArG (M381V) ( fig.  1g ). Patient 8, a 4-mo-old girl, had bilateral optic-nerve aplasia and 1588ArG (T391A) ( fig. 1h ). Further clinical details can be found in appendix A (online only).
All patients except patients 3 and 4 had normal growth, intelligence, results of physical examination, and appearance on CT. Each had a normal karyotype. The mutations detected here occurred on one of the alleles (were thus heterozygous) and were not detected in unaffected immediate family members or in 1100 normal individuals, indicating sporadic occurrence. Since mutations of the PAX2 gene were detected in patients with optic-nerve anomalies associated with renal anomaly (PRS) (Sanyanusin et al. 1995) , we screened for PAX2 but failed to detect any mutation in these patients (data not shown).
Although all the mutations are indicated to be sporadic, each occurred in an important amino acid residue, which suggests that they cause disease. Seven of the eight mutations were missense, one of which was positioned in the paired domain (PD), one in the homeodomain (HD), and five in the proline-serine-threonine-rich transactivating domain (PST). The proline residue at 68 in the PD and the phenylalanine residue at 258 in the HD are conserved throughout all Pax family members identified to date. The serine residues at 292 and 363, the glutamine residue at 378, the methionine residue at 381, and the threonine residue at 391 in the PST are conserved throughout all the vertebrate Pax6 homologues identified to date. Amino acid sequences of the PST are conserved in vertebrates but considerably diversified in invertebrates.
We next performed functional assay of the mutations. The mutant forms of PAX6 cDNAs, generated by PCRbased in vitro mutagenesis, were cloned into plasmids pBluescript and pCAGGS, the latter of which contains a cytomegalovirus enhancer and chicken b-actin promoter (Yamaguchi et al. 1997; Azuma et al. 1999 ). Wild-type and mutant forms of PAX6 proteins were synthesized by in vitro transcription and translation by use of rabbit reticulocyte lysate in the presence of [
35 S] methionine. SDS-polyacrylamide gel electrophoresis and fluorography of the reactions revealed that the PAX6 proteins with expected molecular weights were produced at similar efficiency (data not shown). It is, therefore, unlikely that the mutations affect the efficiency of translation or stability of PAX6 protein.
To examine possible functional changes by the detected mutations, we performed a chloramphenicol acetyltransferase (CAT) assay in mouse embryonic carcinoma P19 cells, which are often used for functional analysis of the PAX6 gene. First, a CAT-reporter construct carrying six copies of P6CON, the consensus binding sequence of the PAX6 PD (Epstein et al. 1994; Yamaguchi et al. 1997) , was used. Wild-type PAX6 strongly activated CAT reporter-gene expression, and the transcriptional activation potential of PAX6 was more or less affected by all the mutations reproducibly, with significant impairment by P68S, Q205X, F258S, and S292I ( fig. 2b) . The mutation within the HD (F258S) impaired the PD-mediated transcriptional activation and is consistent with a report of the functional interplay of the PD and the HD (Mishra et al. 2002) .
In the optic stalk and ventral forebrain of the zebrafish embryo, Pax2 and Pax6 expression is inversely correlated 
Figure 2
Effects of PAX6 on PAX2 (a) and of PAX2 on PAX6 (c). CAT activities were measured in P19 cells after cotransfection of effecter and reporter constructs. Total volume of DNA was adjusted with an empty vector, pBluescript. Cell extracts were prepared after 48 h and assayed for CAT activities by use of a FAST CAT Green Reagent (Molecular Probes). The CAT activity was quantified by measurement with a phospho-fluor-imager (Molecular Dynamics) and illustrated in a fold-activation, compared with the condition with the vector alone. The levels of PAX2 were suppressed with increasing amounts of wild type of PAX6, and vice versa. b, Transactivating potential of PAX6 mutants. 0.1 mg of effecter construct and 1 mg of reporter constructs were cotransfected in P19 cells. Transcription level from P6CON was disturbed significantly by P68S, Q205X, F258S, and S292I mutants and slightly by S363P, Q378R, M381V, and T391A mutants. d, Effects of PAX6 mutants on PAX2 expression. One mg of effecter construct and 1 mg of reporter constructs were cotransfected in P19 cells. The decreasing level of PAX6 was significantly disturbed with the P68S, Q205X, S292I, and M381V mutants. Each photograph of CAT assay under the bar graph is representative of at least three independent experiments. under the control of sonic hedgehog signaling (Macdonald et al. 1995) . Data indicating reciprocal transcriptional repression of Pax2 and Pax6 also were obtained using mouse homologues (Schwarz et al. 2000) . Thus, although PAX2 and PAX6 were initially considered to be transcriptional activators, they also may inhibit transcription of some genes to exert their roles during development. We next examined the effect of PAX6 and PAX2 proteins on activities of PAX2 and PAX6 gene promoters, respectively. A CAT-reporter construct carrying an ∼2-kb PAX6 promoter region (the 1285th to 3381st nucleotides in GenBank accession number U63833), or a 1.2-kb PAX2 promoter region (the Ϫ1002nd to ϩ190th nucleotides in GenBank accession number U45245) was used. When an increasing amount of the PAX6 or PAX2 expression construct was cotransfected into P19 cells with a constant amount of the PAX2 or PAX6 reporter construct, each CAT activity decreased in a dose-dependent manner, indicating that PAX6 represses PAX2 gene expression and vice versa ( fig. 2a and  2c) . By use of this assay system, we evaluated possible effects of the PAX6 mutations on PAX2 promoter activity. Four expression constructs carrying P68S, Q205X, S292I, or M381V mutations failed to repress the PAX2 promoter activity, unlike the wild-type PAX6 and other mutant constructs ( fig. 2d ). These mutations were found with morning glory disc anomaly or ONH and caused a functional change in our experimental system. Because PAX2 mutations were also found in coloboma and ONH (Sanyanusin et al. 1995) , we speculate that failure of the PAX6-PAX2 regulatory circuit may affect phenotypic manifestations of these anomalies. Ex-pression of the CAT-reporter gene was probably inhibited by endogenous PAX6 protein to some extent and stimulated by Q205X through its dominant-negative action on endogenous PAX6, as suggested elsewhere (Singh et al. 1998) . Numerous processes are needed for opticnerve formation, so PAX2 and PAX6 may cooperate in optic-nerve formation or occasionally share tasks; for example, opening and closing the embryonic fissure and mutations of either gene cause similar phenotypic changes.
Our patients had a wide variety of optic-nerve malformations, in which a full series of disease-causing events of optic-nerve malformation-including embryonic fissure (coloboma), retinal ganglion cells (ONH/aplasia), and hyaloid vessels (persistent hyperplastic primary vitreous)-are included (Brown and Tasman 1983) . Because Pax6/PAX6 is expressed in numerous tissues important for optic-nerve development-including the CNS, optic stalk, and retinal progenitors at an early stage, and retinal ganglion cells at a late stage-it is not surprising that many more variable phenotypes are caused by PAX6 mutations than by PAX2 mutations.
Genetic analysis indicated that haploinsufficiency of the gene causes the classical aniridia phenotype, in which all eye tissues are affected. Most mutations detected in aniridia result in premature translational termination on one of the alleles (Martha et al. 1994) . In contrast, most missense mutations generate distinctive nonaniridia phenotypes-including anterior segment anomalies, congenital cataracts, and foveal hypoplasia-in which certain eye tissue is affected (Hanson et al. 1999) . Because most of the amino acid residues are conserved, distinct missense mutations may alter the degree and specificity of DNA binding and transcriptional regulation by PAX6 protein to a different extent (Yamaguchi et al. 1997; Azuma et al. 1999) . Some missense mutations are thought to be recurrently associated with a specific phenotype in eye anomalies. Two patients with an R128C mutation, independently identified in Japan and Europe, had the same phenotype, with foveal hypoplasia (Azuma et al. 1996; Hanson et al. 1999) . Mutations associated with Peters anomaly were in the N-terminal subdomain of the PD (van Heyningen and Williamson 2002) . In contrast, a missense mutation in the alternatively spliced exon was associated with a variety of ocular anomaly phenotypes . No distinct positional effect of the missense mutations on phenotypic manifestation of optic-nerve malformations was found in the present study. Because the Pax6/PAX6 gene is expressed repeatedly throughout ocular tissues, these missense mutations probably disturb PAX6 protein function in different ways, which result in various phenotypes.
Besides eye anomalies, patient 3 was mentally retarded, and patient 4 had an enlarged CNS ventricle and a urinary anomaly. PAX6 plays an important role in CNS development, and CNS malformation and mental retardation associated with PAX6 mutations have been reported (Malandrini et al. 2001; Sisodiya et al. 2001) . However, gene expression in the urinary tract was not reported. It is unknown if patient 4 carries compound mutations of the separate genes related to eye or urinarytract development, or whether PAX6 is slightly, or for a short time, expressed in the urinary tract. Because PAX2 is expressed in the kidney, extensive analysis of expression and correlation of PAX6 and PAX2 throughout development would validate the significance of the genes in pathogenesis of the diseases in which multiple organs are involved.
